PerkinElmer helps accelerate gene therapy research with ready-to-use viral vector assays

Nov. 22, 2022
Streamlined workflows aim to shorten research and development for novel therapies to combat diseases like cancer and Alzheimer's.

PerkinElmer, Inc launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. 

The validated and fully automatable assays are built on PerkinElmer's proprietary AlphaLISA technology which requires no separation.

Designed to streamline gene therapy research and development workflows with an easier-to-use and more high throughput method, each of the seven kits detects specific serotypes to target different cell types in the body for gene therapy application.

PerkinElmer release